Review
Cardiac & Cardiovascular Systems
Hao Jin, Jianfeng Xu, Zheng Sui, Lili Wang
Summary: This meta-analysis evaluates the association between risk factors in the Framingham risk score (FRS) and anthracycline-induced cardiotoxicity in breast cancer patients. The study finds that hypertension, hyperlipidemia, diabetes, smoking, and obesity are associated with an increased risk of cardiac events.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Geriatrics & Gerontology
Hui Shi, Mei-Ling Ge, Birong Dong, Qian-Li Xue
Summary: Higher Framingham CVD risk score was associated with a greater risk of incident frailty among Chinese older adults in this study. However, this association was no longer significant after adjusting for chronological age.
Article
Oncology
Alzina Koric, Chun-Pin Chang, Bayarmaa Mark, Kerry Rowe, John Snyder, Mark Dodson, Vikrant G. Deshmukh, Michael G. Newman, Alison M. Fraser, Ken R. Smith, Ankita P. Date, Lisa H. Gren, Christina A. Porucznik, Benjamin A. Haaland, N. Lynn Henry, Mia Hashibe
Summary: The risk of cardiovascular disease (CVD) is slightly higher among long-term breast cancer survivors in the 10 to 15 years following their cancer diagnosis compared to the general population. Factors such as higher comorbidity index score, older age, obesity, lower education, and family history of CVD and breast cancer were associated with an increased risk of CVD among long-term breast cancer survivors.
Article
Oncology
Maria Sund, Miguel Garcia-Argibay, Hans Garmo, Johan Ahlgren, Anna-Karin Wennstig, Irma Fredriksson, Henrik Lindman, Antonis Valachis
Summary: This study found an increased risk for arrhythmia and acute ischemic heart disease in breast cancer patients treated with AIs for more than four years. This conclusion should be taken into consideration in the risk-benefit assessment of endocrine therapy.
Article
Oncology
Joseph A. DeMari, Emily Dressler, Randi E. Foraker, Brian J. Wells, Sydney Smith, Heidi Klepin, William G. Hundley, Glenn J. Lesser, David I. Shalowitz, Chandylen L. Nightingale, Marcia Hernandez, Kathryn E. Weaver
Summary: This study found that endometrial cancer survivors have a positive attitude towards discussing cardiovascular disease risk during oncology care. Strategies are needed to implement cardiovascular disease risk assessment guidelines and enhance communication and referrals with primary care.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
A. -K. Wennstig, H. Garmo, L. Wadsten, B. Lagerqvist, I. Fredriksson, L. Holmberg, C. Blomqvist, G. Nilsson, M. Sund
Summary: Adjuvant radiotherapy for breast cancer is associated with an increased risk of coronary artery stenosis, particularly in women who receive left-sided radiation. Implementing and further developing techniques that lower cardiac doses is important in reducing the risk of long-term side effects.
STRAHLENTHERAPIE UND ONKOLOGIE
(2022)
Article
Cardiac & Cardiovascular Systems
Nader Saki, Hossein Babaahmadi-Rezaei, Zahra Rahimi, Maedeh Raeisizadeh, Fateme Jorfi, Faeze Seif, Bahman Cheraghian, Hossien Ghaderi-Zefrehi, Maryam Rezaei
Summary: This cohort study examined the association between modifiable risk factors and Framingham risk score in the prediction of 10-year risk of cardiovascular diseases in an Arab community in Iran. Results showed that hypertension, smoking, physical activity, diabetes, cholesterol, and HDL were independently associated with the CVD risk in both genders. Hypertension and diabetes had the largest AUC values in men, while physical activity had the highest AUC value in women.
BMC CARDIOVASCULAR DISORDERS
(2023)
Article
Public, Environmental & Occupational Health
X. Chen, Q. Tu, D. Wang, J. Liu, Y. Qin, Y. Zhang, Q. Xiang
Summary: The objective of this study was to evaluate the effectiveness of the China-PAR and Framingham risk score in predicting the 10-year risk of CVD in Chinese hypertensive patients. The study found that both models tended to overestimate the risk of CVD, and performed better in males in terms of calibration.
Article
Medicine, Research & Experimental
Azizallah Dehghan, Sajjad Ahmadnia Motlagh, Rozhan Khezri, Fatemeh Rezaei, Dagfinn Aune
Summary: This study aims to investigate the agreement and correlation between laboratory-based and office-based Framingham models for cardiovascular disease risk assessment. The results showed substantial agreement and strong correlation between the two models in both the overall population and different subgroups. The office-based model is more practical and reliable in countries with limited resources.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Lin Jin, Jianxiong Chen, Lingheng Wu, Mengjiao Zhang, Jiali Sun, Cuiqin Shen, Lianfang Du, Dingqian Wang, Zhaojun Li
Summary: The relative importance of arterial stiffness in different cardiovascular disease (CVD) risk scores was verified in a large sample of Chinese women. Arterial stiffness showed significant positive correlations with CVD risk scores and exhibited higher importance in predicting risk scores compared to traditional risk factors. These findings suggest the potential use of arterial stiffness measurements in CVD risk assessment.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Oncology
Kathryn P. Lowry, Laura Ichikawa, Rebecca A. Hubbard, Diana S. M. Buist, Erin J. A. Bowles, Louise M. Henderson, Karla Kerlikowske, Jennifer M. Specht, Brian L. Sprague, Karen J. Wernli, Janie M. Lee
Summary: In women with previously treated breast cancer, the risk of second breast cancers is higher in those with ER-negative primary cancer during the first 5 years after diagnosis compared to those with ER-positive cancer.
Article
Health Care Sciences & Services
Sazzli Shahlan Kasim, Nurulain Ibrahim, Sorayya Malek, Khairul Shafiq Ibrahim, Muhammad Firdaus Aziz, Cheen Song, Yook Chin Chia, Anis Safura Ramli, Kazuaki Negishi, Nafiza Mat Nasir
Summary: This study validated and compared the performance of four cardiovascular disease risk prediction models in an Asian population. The FRS and RPCE models showed good discrimination but poor calibration in predicting CVD risk. SCORE2 and RPCE outperformed their previous versions, SCORE and PCE, respectively.
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2023)
Article
Public, Environmental & Occupational Health
Avonne E. Connor, Kate E. Dibble, Kala Visvanathan
Summary: This study describes breast cancer survivorship factors among Black breast cancer survivors in Maryland, with a focus on obesity, comorbidity, and behavioral factors associated with cardiovascular disease (CVD) risk. Utilizing social media recruitment strategies and survivor networks, we recruited 100 Black female breast cancer survivors to complete an online survey. The study identified at-risk breast cancer survivors in Maryland due to the high prevalence of CVD risk factors.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Oncology
Matteo Franchi, Roberta Tritto, Luigi Tarantini, Alessandro Navazio, Giovanni Corrao
Summary: For post-menopausal women with estrogen-receptor-positive breast cancer, treatment with aromatase inhibitors reduces disease recurrence and mortality compared to tamoxifen, but it also increases the risk of heart failure and cardiovascular events, especially in patients with existing cardiovascular risk factors. The interdisciplinary collaboration between oncologists and cardiologists is crucial in evaluating the risk/benefit ratio of hormone therapy choice.
Article
Oncology
Kyae Hyung Kim, Seulggie Choi, Kyuwoong Kim, Jooyoung Chang, Sung Min Kim, Seong Rae Kim, Yoosun Cho, Yun Hwan Oh, Gyeongsil Lee, Joung Sik Son, Sang Min Park
Summary: The study found that even small amounts of physical activity may help decrease the risk of cardiovascular disease, coronary heart disease, and stroke in breast cancer survivors. However, the benefits of physical activity for obese and overweight breast cancer survivors were smaller compared to those with normal weight. The frequency of moderate-to-vigorous physical activity (MVPA) showed a reverse J-curve association with cardiovascular disease, with the best benefit observed in the group engaging in 3-4 times MVPA per week.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Julienne E. Bower, Ann H. Partridge, Antonio C. Wolff, Steve W. Cole, Michael R. Irwin, Elissa D. Thorner, Hadine Joffe, Laura Petersen, Catherine M. Crespi, Patricia A. Ganz
Summary: This study examined the effects of interventions on younger breast cancer survivors and found that mindful awareness practices (MAPs) had beneficial effects on psychological and immune outcomes, indicating its potential for enhancing biobehavioral health.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Review
Hematology
Nadia R. Sutton, Rajeev Malhotra, Cynthia St. Hilaire, Elena Aikawa, Roger S. Blumenthal, Grace Gackenbach, Parag Goyal, Adam Johnson, Sagar U. Nigwekar, Catherine M. Shanahan, Dwight A. Towler, Brooke N. Wolford, Yabing Chen
Summary: Cardiovascular disease is the leading cause of death globally, particularly in individuals over the age of 65, with myocardial infarction and stroke being the primary contributors. The development of vascular aging and vascular calcification with aging is not fully understood, but is believed to be influenced by genetic risk, environmental factors, and the ability of vascular smooth muscle cells to acquire an osteogenic phenotype. Understanding the molecular mechanisms behind age-associated vascular pathology may lead to strategies for promoting healthy vascular aging. This article provides a summary of current knowledge on age-associated vascular disease, with a focus on vascular calcification.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Editorial Material
Oncology
Cesar A. Santa-Maria, Antonio C. Wolff
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zhengyi Deng, Miranda R. Jones, Mei-Cheng Wang, Antonio C. Wolff, Kala Visvanathan
Summary: Higher cancer mortality was observed among Non-Hispanic Black and Hispanic survivors, while higher cardiovascular mortality was observed among Non-Hispanic Black survivors among women who survive a first breast cancer to develop a second primary cancer.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Cardiac & Cardiovascular Systems
Yaa A. Kwapong, Ellen Boakye, Sadiya S. Khan, Michael C. Honigberg, Seth S. Martin, Chigolum P. Oyeka, Allison G. Hays, Pradeep Natarajan, Mamas A. Mamas, Roger S. Blumenthal, Michael J. Blaha, Garima Sharma
Summary: Depression and poor mental health are associated with increased risk of cardiovascular disease and suboptimal cardiovascular health among young adults.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Oncology
Jennifer Y. Sheng, Claire F. Snyder, Katherine C. Smith, Jennifer DeSanto, Nancy Mayonado, Susan Rall, Sharon White, Amanda L. Blackford, Fabian M. Johnston, Robert L. Joyner, Joan Mischtschuk, Kimberly S. Peairs, Elissa Thorner, Phuoc T. Tran, Antonio C. Wolff, Youngjee Choi
Summary: Survivorship care plans (SCPs) are important for communicating cancer-related information. This study found that some tests conducted after SCP receipt were not consistent with guidelines, indicating overuse. This analysis identifies areas for improvement in guideline-concordant care.
Article
Oncology
Gabrielle B. Rocque, Courtney Andrews, Valerie M. Lawhon, Rachel Frazier, Stacey A. Ingram, Mary Lou Smith, Lynne I. Wagner, Lisa Zubkoff, Nadine Tung, Lauren P. Wallner, Antonio C. Wolff
Summary: As outcomes improve in early-stage breast cancer, clinical trials are shifting towards optimization trials, which aim to use less toxic therapy while maintaining survival outcomes. However, little is known about physician perspectives on the barriers and facilitators to enrollment in these trials and the generalizability of the results.
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
Susana L. Garcia-Recio, Toshinori J. Hinoue, Gregory L. C. Wheeler, Benjamin J. Kelly, Ana C. A. Garrido-Castro, Tomas Pascual, Aguirre A. M. De Cubas, Youli B. Xia, Brooke M. Felsheim, Marni B. McClure, Andrei A. Rajkovic, Ezgi Karaesmen, Markia A. Smith, Cheng E. Fan, Paula I. Gonzalez J. Ericsson, Melinda E. Sanders, Chad J. Creighton, Jay T. Bowen, Kristen Leraas, Robyn T. Burns, Sara Coppens, Amy L. Wheless, Salma S. Rezk, Amy L. K. Garrett, Joel S. Parker, Kelly K. H. Foy, Hui Shen, Ben H. Park, Ian Krop, Carey F. Anders, Julie Gastier-Foster, Mothaffar F. U. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly J. Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael Davis, Jonathan C. Silverstein, Alexander G. Ropelewski, Minetta C. Liu, Susan G. L. Hilsenbeck, Larry Norton, Andrea L. C. Richardson, W. Fraser E. Symmans, Antonio C. A. Wolff, Nancy E. V. Davidson, Lisa A. M. Carey, Adrian V. A. Lee, Justin M. W. Balko, Katherine A. R. Hoadley, Peter W. A. Laird, Elaine R. A. Mardis, Tari A. A. King, Charles M. AURORA US Network, Charles M. Perou
Summary: The AURORA US Metastasis Project aimed to identify molecular features associated with metastasis in breast cancer. By analyzing the samples from 55 females with metastatic breast cancer, changes in gene expression subtypes and DNA clonality shifts were observed. Downregulation of estrogen receptor (ER)-mediated cell-cell adhesion genes through DNA methylation mechanisms was observed in metastases. Differences in the tumor microenvironment and immune cell infiltrates were also found in different breast cancer subtypes, providing implications for targeted therapies.
Review
Oncology
Laura Pala, Tommaso De Pas, Eleonora Pagan, Isabella Sala, Chiara Catania, Emma Zattarin, Paolo Arnone, Massimo M. Grassi, Marco Colleoni, Antonio C. Wolff, Javier Cortes, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Vincenzo Bagnardi, Fabio Conforti
Summary: This study conducted a systematic review and meta-analysis of randomized clinical trials to compare the efficacy of limited-extended adjuvant endocrine treatment (ET) and full-extended ET in patients with early-stage breast cancer. The results showed that full-extended ET significantly improved disease-free survival (DFS) in patients with nodal-positive disease, while no significant improvement was observed in other subgroups.
Article
Oncology
Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison
Summary: This article is an update on the recommendations for HER2 testing in breast cancer, affirming the 2018 ASCO-CAP recommendations. The article emphasizes a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified, and provides best practice recommendations to distinguish IHC 0 and 1+.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Christeen Samuel, Jihwan Park, Aparna Sajja, Erin D. Michos, Roger S. Blumenthal, Steven R. Jones, Seth S. Martin
Summary: This study compared the accuracy of 23 available LDL-C equations with ultracentrifugation measurement and found that most alternatives to the Friedewald equation have lower accuracy. The Martin/Hopkins equation demonstrated the highest accuracy overall and across subgroups.
Article
Oncology
Beverly Moy, Antonio C. Wolff, R. Bryan Rumble, Kimberly H. Allison, Lisa A. Carey
JCO ONCOLOGY PRACTICE
(2023)
Editorial Material
Oncology
Antonio C. Wolff
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zhengyi Deng, Miranda R. Jones, Antonio C. Wolff, Kala Visvanathan
Summary: The UK National Health Service's Predict tool performs well in predicting breast cancer-specific mortality for first breast cancer, but underestimates it for second breast cancer, especially for estrogen receptor-positive breast cancer patients.
JNCI CANCER SPECTRUM
(2023)
Article
Oncology
Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Pare, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer
Summary: This study reports the long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab, and establishes potential biomarkers to predict prognosis. The results indicate that adjuvant paclitaxel and trastuzumab is a reasonable treatment standard for this population, and the HER2DX genomic tool might help refine the prognosis.